Flecainide Propafenone

The key electrophysiologic effect is suppression of the rapid phase 0 upstroke in cardiac action potentials. By limiting fast sodium-channel activity, these drugs reduce the speed at which impulses propagate through cardiac tissue. This conduction slowing explains their usefulness against selected supraventricular tachyarrhythmias and also explains why excessive effects can appear as QRS widening on ECG.

Propafenone has an additional beta-adrenergic blocking action, whereas both drugs share fast sodium-channel blockade as a major mechanism. This distinction matters because the agents are not pharmacologically identical even though they affect cardiac conduction in a related way. Recognizing the added activity helps pharmacologists and clinicians interpret their differing effects and avoid treating the two therapies as completely interchangeable.

A widened QRS complex reflects stronger slowing of ventricular impulse conduction, an important consequence of fast sodium-channel blockade. Excessive conduction delay can accompany serious ventricular arrhythmias. The concern is particularly important in patients with structural heart disease, so QRS changes provide a clinically relevant reason for careful patient selection and ECG monitoring during treatment.

Clinicians may consider these drugs when the therapeutic goal is to restore or maintain sinus rhythm in selected patients with atrial fibrillation, atrial flutter, or other supraventricular tachyarrhythmias. Their use therefore centers on rhythm control in appropriate candidates, not on treating every abnormal rhythm. Selection must account for the conduction-related risks associated with Class Ic therapy.

ECG monitoring helps assess whether conduction slowing is becoming excessive during therapy. Clinicians can observe the QRS complex, whose widening reflects an important effect of sodium-channel blockade. This surveillance supports safer patient selection and ongoing management by identifying a pharmacologic response associated with increased concern for serious ventricular arrhythmias, especially when structural heart disease is present.

Effective treatment is intended to restore or maintain sinus rhythm, thereby controlling selected abnormal atrial rhythms such as atrial fibrillation and atrial flutter. The relevant outcome is rhythm control rather than simply demonstrating sodium-channel blockade. Because the same conduction effect that supports treatment can also promote dangerous ventricular arrhythmias, achieving this goal requires balancing rhythm benefit against ECG findings and patient-specific risk.